Recipe Book for Medication-Assisted Treatment (MAT) Integration

May 31, 2017

Jeff Watts, MD Psychiatrist and Addiction Medicine Physician Cook County Health & Hospitals System

## **Disclaimers and Appreciation**

- I do not receive any funding—honoraria, contractual, research, or otherwise— from any pharmaceutical or healthcare company
- I do not have investments or ownership in any pharmaceutical or healthcare company
- Many of the graphical slides in today's presentation are from PCSS-MAT (the Providers' Clinical Support System for Medication Assisted Treatment). I appreciate the use of these materials in today's presentation.

## **Recipe Book for MAT Integration Teaching Objectives**

- To understand the optimal staffing and patient care models for MAT services
- To learn about critical training and logistical issues needed for implementation
- To discuss common system and patient-care challenges with starting MAT services

#### **Definitions of Addiction**

- Is a primary, chronic disease of brain reward, motivation, memory and related circuitry that leads to characteristic biological, psychological, social and spiritual manifestations— ASAM
- Is a mental, physical, and spiritual disease—Big Book of AA
- Is a chronic, relapsing brain disease that is characterized by compulsive drug seeking and use, despite harmful consequences—NIDA

An addict is not a *bad* person trying to get *good*, but is a *sick* person trying to get *well* 

#### DSM-5 Criteria for Substance Use Disorder: Recommendations and Rationale

	DSM-IV Abuse <sup>a</sup>		DSM-IV Dependence <sup>b</sup>		DSM-5 Substance Use Disorders <sup>c</sup>	
Hazardous use	X	ו	-		х	ו
Social/interpersonal problems related to use	Х	≥1	-		х	
Neglected major roles to use	Х	criterion	-		х	
Legal problems	Х	J	-		_	
Withdrawal <sup>d</sup>	-		х	ו	х	
Tolerance	-		х		х	≥2
Used larger amounts/longer	-		x		х	criteria
Repeated attempts to quit/control use	-		x	≥3 criteria	х	
Much time spent using	-		X	Criteria	х	
Physical/psychological problems related to use	-		x		х	
Activities given up to use	-		X	J	х	
Craving	_		_		х	J

#### **Figure Legend:**

DSM-IV and DSM-5 Criteria for Substance Use Disorders<sup>a</sup> One or more abuse criteria within a 12-month period and no dependence diagnosis; applicable to all substances except nicotine, for which DSM-IV abuse criteria were not given.

<sup>b</sup> Three or more dependence criteria within a 12-month period.

<sup>c</sup> Two or more substance use disorder criteria within a 12-month period.

<sup>d</sup> Withdrawal not included for cannabis, inhalant, and hallucinogen disorders in DSM-IV.

Cannabis withdrawal added in DSM-5. SEVERITY INDICATORS: Use number of criteria met (from 2

to 11) as an overall severity indicator mild (2-3 criteria), moderate (4-5), and severe (6 or more) disorders.



Hasin et al., 2013, Am J Psychiatry

### **Recipe Book for MAT Integration** Introduction to MAT

- MAT stands for Medication Assisted Treatment for addictive disorders or substance use disorders (SUDs)
- Currently refers to FDA-approved treatments for nicotine, alcohol, and opioid/heroin use disorders
- There are also medications that have been "off-label" due to known effects on SUDS
- Many clinical trials are examining novel medications, drugs and vaccines for possible MAT use

#### <u>Currently Available Medications</u> For Nicotine/Tobacco Use Disorders

- For cessation or relapse
- Nicotine replacement (gum, patches, spray, lozenges)
- Buproprion (Zyban, Wellbutrin)
- Varenicline (Chantix)


#### <u>Currently Available Medications</u> For Alcohol Use Disorders

- Acute Withdrawal (Benzodiazepines—longer acting, or off-label anticonvulsants)
- Relapse Prevention
  - Disulfiram (Antabuse)
  - Acamprosate (Campral)
  - Naltrexone (Oral tablets-ReVia; XR Injection-Vivitrol)

#### <u>Currently Available Medications</u> For Opioid Use Disorders

- Full agonist (methadone)—from a specialized, certified, and licensed methadone provider
- Partial agonist (buprenorphine)
  - For withdrawal, detox, or maintenance
  - Available in tablets, SL films, buccal films, and now implant
  - Brand names include Suboxone, Zubsolv, Bunavail, Probuphine (implant)
- Antagonist (Naloxone-Narcan; Naltrexone-ReVia, Vivitrol)

#### **Comparison of Activity Levels**



#### What is the best recipe for a MAT Clinic

- Utensils and appliances needed
- Key ingredients
- Recipe with exact amounts
- Cooking/culinary skills
- Tasting/eating
- Making changes for the next time





#### What is the best recipe for a MAT Clinic?

• Utensils and appliances needed

Site Visit, Pharmacy, Lab Issues

• Key ingredients

- Staff Hiring, Training
- Recipe with exact amounts

Prescribers + "Glue Person"

- Cooking/culinary skills
- Direct care, procedures, logistics

Tasting/eating

Start seeing and treating patients

Making changes for the next time

Evaluation, lunch-n-learn, e-consults

- Opioid Addicted Patients
- Trained Prescribers
- MAT Coordinator

**Opioid Addicted Patients** 

- Heroin vs. Prescription Opioids<sup>1</sup>
- Motivated vs. Mandated vs. Monitored Patients
- Chronic Pain / Physiologically Dependent Patients
- Co-morbid medical illnesses or psychiatric disorders

Prescriber of MAT

- Physicians must complete 8 hour "waiver training" and receive special DEA X-number
- As of end of 2016, Nurse Practitioners (APNs) and Physician Assistants (PAs) may complete 24 hours of training<sup>2</sup> and apply for prescriptive authority
- Number of allowed patients varies—from 30 to 100 to 275
- Most often reported barrier to MAT implementation is inexperience/concern for withdrawal in initial patient inductions

MAT Coordinator / "Glue Person"

- Could be CADC, LCSW, MSW, LPN, RN, Other
- Is primary conduit between patients and prescribers
- Manages referrals, scheduling, medication availability issues, patient tracking
- May conduct on-site MAT groups or connects with community providers/groups
- Is available for patients and trouble shoots often on a daily basis

- Clinical Space
- Medication Availability
- Behavioral Treatment

**Clinical Space** 

- No specific requirements
- Helpful to have bathroom nearby for urine toxicology screens and GI issues in opioid withdrawal
- Ideal to have 2 patient rooms so that prescriber (MD, NP, PA) can be monitoring an induction while also seeing other MAT or primary care patients simultaneously
- No emergency equipment needed. COWS only requires phone/watch (for pulse) and pen light (for pupil dilation).
- Need a small conference or group room on weekly basis (if onsite MAT groups are to be facilitated)

**Medication Availability** 

- Bup/Nx tablets are now generic
- Most insurers have Suboxone, Zubsolv, and/or Bunavail are their formularies as well (occasional prior auth)
- Immediate availability of Bup/Nx will dictate the induction model (on-site observed vs. "home" non-observed)
- Partnering with on-site or nearby pharmacy for Bup/Nx
- Naltrexone XR (Vivitrol) is being added to more formularies but prior authorization is often required—very expensive
- If stocking/storing Naltrexone XR, will need refrigerator

**Behavioral Treatment** 

- On-site MAT groups
- 12 Step groups (AA, NA, others)
- SMART Recovery
- Refuge Recovery
- Referral to IOP or other treatment program
- Individual Therapy

### **Recipe Book for MAT Integration Skills Needed, Cooking Times**

- Models of Induction
- Clinical Tools / Toxicology Tests
- Patient Flow/Scheduling
- Clinic Management/Common Problems
  - Diversion, Other SUDs, Pain

- Delivery—patient already inducted at another site
- Made from Scratch—on-site assessment, induction, monitoring
- Out of a Box—on-site instructions with "home" non-observed induction

Delivery

- Comes to your clinic already on MAT
- From hospital  $\text{ER}^5$  or inpatient ward<sup>6</sup>
- From correctional setting<sup>7</sup>
- From induction center (hub-and-spoke model)<sup>8</sup>
- From substance abuse tx center
  - Detox, residential, sober living

#### Made from Scratch

- Traditional model taught in waiver training
- Inductions are on-site and observed (COWS Instrument)
- Requires prep time (pre-assessment), space for extended period (on induction day), med availability, and more staff time
- Ensures Bup/Nx taken correctly and able to monitor for precipitated withdrawal
- Proposed to have greater retention<sup>10</sup> and less diversion than the "home induction" model

#### Out of the Box

- Patients are given a prescription and instructions—written, online, video—on when and how to take Bup/Nx
- Patients have to assess timing of their last use and severity of withdrawal before taking medication (SOWS instrument)
- Does not require extended clinic visit or space occupation
- Does not require on-site medication
- A very good option in patients who have been previously prescribed Bup/Nx maintenance, who have been given Bup/Nx for detox purposes, or who have successfully used on the streets/via diversion

#### Observed vs. Unobserved

Potential factors to consider	Observed	Unobserved
Effective and tolerability	+++	+(+)
Establish treatment structure	+++	-
Development of therapeutic alliance	++	_/+
Confirm baseline withdrawal (and presence of physiologic dependence	+++	-/+*
Convenience/preference		
MD	_/+	+++
Patient	_/+	++
Resources/cost		+
Co-morbidity	_/+	_/+

\* Note: pt's can present for evaluation in mild withdrawal but start Bup out of the office



45

#### **<u>Recipe Book for MAT Integration</u> Clinical Tools / Toxicology Testing**

- Screening and assessment tools
- Patient-centered educational materials (including Naloxone training), patient-provider agreement
- Other helpful documents—sample induction notes/progress notes, policy/procedures, FAQs for covering physicians, billing information, protocol/algorithm, implementation checklist
- Prescription monitoring website

#### **<u>Recipe Book for MAT Integration</u> Clinical Tools / Toxicology Testing**

#### **Toxicology Testing**

- Urine vs. Saliva—ease of use, \$\$, detection window
- Send-out lab—know what is tested for
- POC testing—likely need assay with high detection of opiates (eg 300 ng/dl)
- POC testing—need separate methadone, buprenorphine, oxycodone, and, maybe, fentanyl

#### **Recipe Book for MAT Integration Patient Flow / Scheduling**

- Three phases of treatment—induction, stabilization, and maintenance
- Guidelines are continually changing (TIPS reference)
- After induction, a followup visit or call the next day is recommended
- $\boldsymbol{\cdot}$  At our sites, we provide
  - a one-week rx for 4-6 weeks
  - $\cdot$  two week rx for the following 6-8 weeks, then
  - monthly thereafter
  - issues with lost rx, diversion, problematic tox results resets the process
- As in cooking, MAT clinic flow and scheduling is often dictated by the shape in which it was prepared. Your management may differ based upon staffing, space, capacity, etc. within your clinic.

#### **Recipe Book for MAT Integration Patient Management / Common Issues**

- MAT Coordinator keeps tracking log to know when rx are due, most recent toxicology results, current schedule (weekly, biweekly, monthly), other
- Anticipate / Plan for Common Issues
  - Urine toxicology positive for opiates, methadone, fentanyl
  - Urine toxicology negative for buprenorphine
  - Urine toxicology repeatedly + for THC, BZD, cocaine, PCP, amphetamine
  - Patient seeking BZDs or prescription opiates / tramadol
  - Lost/stolen prescriptions
  - Missed/late appointments—policy around walk-ins
  - Patient seeking BZDs

#### **Recipe Book for MAT Integration Patient Management / Common Issues**

- How to manage
  - Opioid Dependence and Co-Morbid Psychiatry Issues
  - Opioid Dependence and Other SUDs (alcohol, cocaine, BZD, other)
  - Chronic Pain
  - Acute Pain (surgeries, trauma, etc)



#### Medications as part of MAT services are not the solution, but may be a key part to it

## At best, the MAT component can help persons with SUDs reach sobriety/recovery sooner

At worst, the MAT component may help prevent a person from overdosing and allow them to live one more day



# The opioid epidemic is enormous in scope

There is much funding/grants, trials, programs, task forces, clinical passion, and political fervor about how to address the epidemic

Fortunately, a result of the hysteria is a complex but extensive support, education, training, and mentoring network for MAT

As we tell our patients, don't be afraid to ask for help!!

#### References

- Weiss, RD et al. Longterm outcomes from NIDA CTN Prescription Opioid Addiction Treatment Study (POATS). Drug Alcohol Depend (2015) 150: 112-119.
- 2. Waiver training curricula for NPs/PAs through PCSS-MAT—<u>http://pcssmat.org</u> or ASAM—<u>http://elearning.asam.org</u>.
- 3. Kissin, W et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis (2006) 25: 91-103.
- 4. Egan, JE et al. PCSS-B: a novel project to expand/improve buprenorphine treatment. J Gen Intern Med (2010) 25: 936-941.
- D'Onofrio, G et al. Emergency department-initiated buprenorphine/ naloxone treatment for opioid dependence: a randomized clinical trial. JAMA (2015) 313:1636-1644.
- Liebschutz, J et al. Buprenorphine treatment for hospitalized, opioiddependent patients: a randomized clinical trial. JAMA Intern Med (2014) 174:1369-1376.

#### References

- 7. Ludwig, AS; Peters, RH. MAT for opioid use disorders in correctional settings: an ethics review. Int J Drug Policy (2014) 25:1041-1046.
- 8. Gunderson, EW et al. Improving temporal efficiency of outpatient buprenorphine induction. Am J Addictions (2011) 20: 397-404.
- 9. Cassadonte, PP; Sullivan, MA. Buprenorphine induction. PCSS guidance from PCSS-MAT. (Updated Nov 27, 2013). <u>http://pcssmat.org</u>.
- 10. Fiellin, DA et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. NEJM (2006) 355: 365-374.
- Gunderson, EW et al. Unobserved versus observed office buprenorephine/naloxone induction: a pilot randomized clinical trial. Addict Behav (2010) 35: 537-540.